| PD-1 blockade in tumors with mismatch-repair deficiency DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ... New England Journal of Medicine 372 (26), 2509-2520, 2015 | 9653 | 2015 |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6160 | 2017 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3109 | 2013 |
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer RM Goldberg, DJ Sargent, RF Morton, CS Fuchs, RK Ramanathan, ... Journal of Clinical Oncology 22 (1), 23-30, 2004 | 2983 | 2004 |
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer CM Ribic, DJ Sargent, MJ Moore, SN Thibodeau, AJ French, ... New England Journal of Medicine 349 (3), 247-257, 2003 | 2719 | 2003 |
| Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 J Tepper, MJ Krasna, D Niedzwiecki, D Hollis, CE Reed, R Goldberg, ... Journal of clinical oncology 26 (7), 1086-1092, 2008 | 1557 | 2008 |
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment A Grothey, D Sargent, RM Goldberg, HJ Schmoll Journal of Clinical Oncology 22 (7), 1209-1214, 2004 | 1348 | 2004 |
| Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? S Gill, CL Loprinzi, DJ Sargent, SD Thomé, SR Alberts, DG Haller, ... Journal of clinical oncology 22 (10), 1797-1806, 2004 | 1325 | 2004 |
| A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients DJ Sargent, RM Goldberg, SD Jacobson, JS Macdonald, R Labianca, ... New England Journal of Medicine 345 (15), 1091-1097, 2001 | 1182 | 2001 |
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ... Journal of Clinical Oncology 28 (22), 3617-3622, 2010 | 991 | 2010 |
| Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors NM Lindor, LJ Burgart, O Leontovich, RM Goldberg, JM Cunningham, ... Journal of clinical oncology 20 (4), 1043-1048, 2002 | 983 | 2002 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 842 | 2017 |
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ... Journal of Clinical Oncology 23 (34), 8664-8670, 2005 | 792 | 2005 |
| Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ... Journal of Clinical Oncology 27 (6), 872-877, 2009 | 741 | 2009 |
| Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 CJ Allegra, G Yothers, MJ O'Connell, S Sharif, NJ Petrelli, LH Colangelo, ... Journal of Clinical Oncology 29 (1), 11-16, 2011 | 732 | 2011 |
| Platinum neurotoxicity pharmacogenetics SR McWhinney, RM Goldberg, HL McLeod Molecular cancer therapeutics 8 (1), 10-16, 2009 | 704 | 2009 |
| Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X NM Lindor, K Rabe, GM Petersen, R Haile, G Casey, J Baron, S Gallinger, ... Jama 293 (16), 1979-1985, 2005 | 682 | 2005 |
| Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study SR Alberts, WL Horvath, WC Sternfeld, RM Goldberg, MR Mahoney, ... Journal of clinical oncology 23 (36), 9243-9249, 2005 | 664 | 2005 |
| Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841 J Franko, Q Shi, CD Goldman, BA Pockaj, GD Nelson, RM Goldberg, ... Journal of Clinical Oncology 30 (3), 263-267, 2012 | 641 | 2012 |
| Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer R Pearlman, WL Frankel, B Swanson, W Zhao, A Yilmaz, K Miller, ... JAMA oncology 3 (4), 464-471, 2017 | 605 | 2017 |
